Cardiometabolic syndrome and chronic kidney disease

Area of Science:

• Nephrology
• Cardiology
• Metabolic Diseases

Background:

• Chronic kidney disease (CKD) is a growing public health concern, linked to end-stage renal disease (ESRD) and cardiovascular (CV) mortality.
• Over 8 million Americans are affected by CKD, necessitating effective preventive strategies.
• The cardiometabolic syndrome, a cluster of CV risk factors, is increasingly implicated in CKD development.

Purpose of the Study:

• To explore the relationship between cardiometabolic syndrome and chronic kidney disease.
• To identify key factors mediating the link between cardiometabolic syndrome and CKD.
• To propose preventive strategies for CKD targeting cardiometabolic risk factors.

Main Methods:

• Review of existing evidence implicating cardiometabolic syndrome in CKD pathogenesis.
• Identification of mediating factors such as oxidative stress and renin-angiotensin system activation.
• Analysis of consequences including microalbuminuria and renal structural changes.

Main Results:

• Cardiometabolic syndrome components (obesity, insulin resistance, dyslipidemia, hypertension) contribute to CKD.
• Mediating factors include glomerular hyperfiltration, inflammation, oxidative stress, and growth factor dysregulation.
• Microalbuminuria, inflammation, endothelial dysfunction, and renal tissue changes are consequences.

Conclusions:

• Controlling cardiometabolic syndrome is crucial for CKD prevention.
• Addressing obesity, insulin resistance, dyslipidemia, and hypertension can mitigate CKD risk.
• Reducing the burden of ESRD requires comprehensive management of cardiometabolic health.